The Lynx Group Acquires Upstream Partners to Create a Dynamic Division Catering Directly to the Pharmaceutical and Biotech Space

The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable from the earliest stages of clinical development, throughout the product life cycle to ensure success of any therapy or device. It's this need that TLG has met with the strategic acquisition of Upstream Partners. "The relationships that Burt Zweigenhaft and Upstream Partners have with the most respected and influential key opinion leaders in their respective specialties perfectly complement The Lynx Group's own channels and ecosystems," says Brian Tyburski, CEO, TLG. "Through this acquisition, customers of both companies will be able to interact with and receive expert advice in all areas of the pharmaceutical and biotech space—prelaunch, launch readiness, go-to-market strategies, and life cycle management—with viewpoints from all stakeholders involved in the care of patients.